Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
Neurolixis SAS, Castres, France.
J Psychopharmacol. 2024 Jul;38(7):661-671. doi: 10.1177/02698811241254832. Epub 2024 Jun 2.
The highly selective 5-HT serotonin receptor "biased" agonists NLX-101 and NLX-204 display, like ketamine, potent and efficacious rapid-acting antidepressant (RAAD) activity in the rat chronic mild stress (CMS) model with systemic (i.p.) administration. They rapidly (within 1 day) reverse anhedonia (i.e., CMS-induced sucrose consumption deficit), attenuate working memory deficit (novel object recognition: NOR), and decrease anxiety behavior in the elevated-plus maze (EPM).
Here, we sought to explore the contribution of prefrontal cortex (PFC) 5-HT receptor activation in the RAAD activity of NLX compounds.
RESULTS/OUTCOMES: In male Wistar rats, unilateral PFC microinjections of NLX-204 and NLX-101 (16 µg), like ketamine (10 µg), reproduced the effects of their systemic administration: they reversed CMS-induced sucrose consumption deficit, attenuated anxiety (EPM), and reduced working memory deficits (NOR). In addition, unilateral PFC microinjections of the selective 5-HT antagonist, WAY-100,635 (2 µg), attenuated the beneficial effects of systemic NLX-204 and NLX-101 (0.16 mg/kg i.p.) in the sucrose intake and NOR models, indicating that these compounds exert their RAAD activity specifically through activation of PFC 5-HT receptors.
CONCLUSIONS/INTERPRETATION: These data indicate that 5-HT receptor biased agonists share with ketamine a common neuroanatomical site for RAAD activity, which can be obtained not only by targeting glutamatergic/NMDA neurotransmission (ketamine's primary mechanism of action) but also by activating 5-HT receptors, as is the case for the NLX compounds. The present observations also reinforce the notion that biased agonism at 5-HT receptors constitutes a promising strategy to achieve RAAD effects, with additional benefits against cognitive deficits and anxiety in depressed patients, without ketamine's troublesome side effects.
高选择性 5-羟色胺(5-HT)血清素受体“偏向”激动剂 NLX-101 和 NLX-204 与氯胺酮一样,在慢性轻度应激(CMS)大鼠模型中通过系统(腹腔内)给药显示出有效的快速抗抑郁(RAAD)活性。它们能迅速(在 1 天内)逆转快感缺失(即 CMS 诱导的蔗糖消耗不足),减轻工作记忆缺陷(新颖物体识别:NOR),并降低高架十字迷宫(EPM)中的焦虑行为。
本研究旨在探讨前额叶皮层(PFC)5-HT 受体激活对 NLX 化合物 RAAD 活性的贡献。
结果/结论:在雄性 Wistar 大鼠中,单侧 PFC 微注射 NLX-204 和 NLX-101(16µg),与氯胺酮(10µg)一样,重现了其系统给药的效果:它们逆转了 CMS 诱导的蔗糖消耗不足,减轻了焦虑(EPM),并减少了工作记忆缺陷(NOR)。此外,单侧 PFC 微注射选择性 5-HT 拮抗剂 WAY-100,635(2µg),减弱了系统给予 NLX-204 和 NLX-101(0.16mg/kg 腹腔内注射)对蔗糖摄入和 NOR 模型的有益作用,表明这些化合物通过激活 PFC 5-HT 受体特异性地发挥其 RAAD 活性。
这些数据表明,5-HT 受体偏向激动剂与氯胺酮具有 RAAD 活性的共同神经解剖学靶点,这种靶点不仅可以通过靶向谷氨酸能/NMDA 神经传递(氯胺酮的主要作用机制)获得,还可以通过激活 5-HT 受体获得,NLX 化合物就是这种情况。目前的观察结果也进一步证实了这样一种观点,即 5-HT 受体的偏向激动构成了实现 RAAD 效应的一种有前途的策略,除了具有氯胺酮所没有的抗抑郁患者认知缺陷和焦虑的额外益处外,还具有额外的益处。